Skip to content
DataLookout
Menu

TroFuse-01ANCT07908524

MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Efficacy Phase: Objective Response Rate (ORR)
Timeframe: Up to approximately 66 months
Efficacy Phase: Number of Participants Who Experience at Least One Adverse Event (AE)
Timeframe: Up to approximately 66 months
Efficacy Phase: Number of Participants Who Discontinue Study Intervention Due to an AE
Timeframe: Up to approximately 66 months
Safety Lead-In (Combination Arms Only): Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
Timeframe: Up to approximately 28 days
Safety Lead-In (Combination Arms Only): Number of Participants Who Experience at Least One AE
Timeframe: Up to approximately 66 months
Safety Lead-In (Combination Arms Only): Number of Participants Who Discontinue Study Intervention Due to an AE
Timeframe: Up to approximately 66 months

Secondary (2)

Efficacy Phase: Prostate-Specific Antigen (PSA) Response Rate
Efficacy Phase: Radiographic Progression-Free Survival (rPFS)

Arms and interventions

DocetaxelActive comparator

Participants will receive docetaxel every 3 weeks by intravenous (IV) infusion. Participants will also receive either prednisone or prednisolone daily (or per approved product label).

Sac-TMT (Dose 1)Experimental

Participants will receive sac-TMT monotherapy every 2 weeks (q2w) by IV infusion.

Sac-TMT (Dose 2)Experimental

Participants will receive sac-TMT monotherapy q2w by IV infusion.

Sac-TMT Plus OpevesostatExperimental

Participants will receive sac-TMT q2w by IV infusion in combination with oral administration of opevesostat twice daily until any of the criterion for discontinuation are met. Participants receiving opevesostat will receive fludrocortisone and dexamethasone daily.

Sac-TMT Plus Androgen Receptor Pathway Inhibitor (ARPI): Abiraterone Acetate or EnzalutamideExperimental

Participants will receive sac-TMT q2w by IV infusion in combination with oral administration of an androgen receptor pathway inhibitor (ARPI), either abiraterone acetate daily or enzalutamide daily until any of the criterion for discontinuation are met. Participants receiving abiraterone acetate will also receive either prednisone or prednisolone daily (or per approved product label).

Biologicals: Sacituzumab tirumotecan

Drugs: Rescue medication, Docetaxel, Prednisone, Opevesostat, Abiraterone acetate, Enzalutamide, Prednisolone, Fludrocortisone, Dexamethasone